• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Drug Industry Comments on FDA’s Real-World Evidence Program

Drug Industry Comments on FDA’s Real-World Evidence Program

February 18, 2019
William Myers

Drug sponsors are eager for the FDA to embrace real-world evidence (RWE), but several companies are asking the agency to clarify how it can be used in clinical trials.

Late last year, the FDA invited public comments on a plan for its real-world evidence framework, and it received 30 overall, nine from drugmakers.

One of the major threads in the comments was about data: specifically connectivity, gaps and capture. The framework “does not provide clarity regarding the kinds of data standards required, who is responsible for developing data standards or the process by which FDA will assesses the acceptability of those standards,” Janssen wrote. “Will FDA require different data standards for different data sources (e.g., health insurance claims vs. electronic health records) or for different types of regulatory decisions?”

Another thread was about evidentiary standards and adequate scientific evidence. “There is not enough detail for sponsors to know whether their evidence will satisfy these criteria. We realize that the practice of using RWE for regulatory decision-making outside of addressing safety questions is still in its infancy,” Janssen added.

Some sponsors also latched on to language that suggested the agency might be open to using observational studies that “replicate” randomized trial results and were worried that the word is a little too vague. Sanofi, for instance, urged the FDA to declare that observational studies can be used “to elucidate the degree of consistency” between randomized control trials and observational studies.

Janssen, too, said it had many questions about replicating randomized trials — how will the agency determine how feasible replication is, and which trials would be subject to replication? How will regulators deal with “confounding” studies? Does the agency have metrics for how well randomized trials and real-world evidence line up?

Novartis also suggested that sponsors should be more prominent in the demonstration projects that the FDA is developing. The company commented on the “clear lack of industry (i.e., drug sponsors) participation” in those projects.

Regeneron suggested that the FDA “provide some discussion points to assist sponsors in how best to apply practices or lessons learned from these programs to planned or future studies to assist in regulatory decision-making, particularly in areas of high unmet medical need.”

Novo Nordisk said it would like to see examples of adaptive or Bayesian trial designs, which the FDA has said might help qualify biomarkers for trials. The agency should also be open to using preclinical data for biomarkers, Novo said.

Read the comments here: https://bit.ly/2DKS7s7.

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing